Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.
2 Medical Stocks to Consider Buying in June
by Shaun Pruitt
With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
by Zacks Equity Research
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
by Zacks Equity Research
Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Top Stock Reports for FEMSA, NextEra Energy & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
by Zacks Equity Research
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
by Zacks Equity Research
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
by Zacks Equity Research
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.